{ "docId": "019dd923-622c-750b-8b99-bca3fd68622d", "docSlug": "4c8fe6013c68", "documentTitle": "iRhythm Technologies, Inc. (IRTC)", "authorId": "54_Spruce_Point_Capital", "authorName": "Spruce Point Capital Management", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-18 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 6, "pageCount": 101, "prevPage": 5, "nextPage": 7, "slideType": "executive_summary", "function": "frame_problem", "density": "dense", "nDataPoints": 6, "notes": "The slide serves as a cover/introductory summary for an activist short report.", "elementsJson": [ "headline_text", "paragraph" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/6", "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d", "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-6", "components": [ { "bbox": null, "kind": "callout", "text": "We disagree and see 40% to 70% downside risk in iRhythm shares.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-0395-748f-9564-a5e1bdc23222", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "metric", "text": "downside risk: 40% to 70%", "attrs": null, "subkind": "primary", "toolName": "Quantification", "toolSlug": "quantification", "confidence": null, "componentId": "019dd953-0395-748f-9564-a993885bd6ad", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.45, "w": 0.96, "x": 0.02, "y": 0.18 }, "kind": "paragraph", "text": "After conducting a forensic review of iRhythm Technologies, Inc. (Nasdaq: IRTC) (\"iRhythm\" or the \"Company\"), including a proprietary survey of 100 practicing cardiologists, we have serious concerns about the safety and competitiveness of the Company’s products, the growth potential of the oft-touted asymptomatic market, looming business headwinds (particularly when coupled with the Company’s poor profitability), and, perhaps most of all, the credibility of its management team. We see troubling signs that iRhythm’s regulatory problems may yet worsen, as recently unsealed legal filings suggest the Department of Justice (DOJ) is investigating a cover-up by the Company’s management. We believe investors have cut iRhythm management too much slack and have failed to properly acknowledge the magnitude of the Company’s failures. U.S. Food and Drug Administration (FDA) evidence suggests iRhythm’s own analysis revealed multiple product deficiencies that threatened the lives of patients. Yet, by the time it was first called out by the FDA in 2022, at least three years had lapsed without the Company taking any action to address complaints or warn patients or cardiologists. During this period of inaction, depending on the issue referenced, iRhythm insiders cashed out of approximately $90 to $160 million of Company stock. Based on FDA evidence, we believe iRhythm violated several of the most basic regulatory processes meant to protect patient safety. Investors are acting as though the Company’s regulatory risks have been fully remediated and that new market opportunities will be realized, which have driven a 141% increase in its share price over the past year. We disagree and see 40% to 70% downside risk in iRhythm shares.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "39136412-6632-4eef-83c2-00d7fe0da9c1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.3, "w": 0.96, "x": 0.02, "y": 0.68 }, "kind": "paragraph", "text": "iRhythm manufactures ambulatory cardiac monitors designed to detect arrhythmias and other cardiac abnormalities that can indicate atrial fibrillation (AFib), which can lead to strokes, heart attacks, or blood clots. The Company’s first product was the Zio XT (updated and renamed “Zio Monitor”), which is a wearable long-term cardiac monitor (LTCM) that records a patient’s electrocardiogram (ECG or EKG) data for up to 14 days. Following the prescribed wear period, the device is mailed to iRhythm, where it is analyzed by the Company’s Zio ECG Utilization Software (“ZEUS”) System and certified radiographic technicians (CCTs), who then send a final report to the cardiologist. The device is generally prescribed by a cardiologist after some sort of patient cardiac event, such as syncope (i.e., fainting) or palpitations. Traditionally, such data was gathered using a Holter monitor, which employed a bulky device with numerous leads/contact points and had a short 1 to 2 day wear period. The Zio XT was one of the first extended wear monitors and has captured a dominant (~70%) share of the market. However, due to the long lag time between prescription and cardiologist receipt of patient results (as long as a month or more), the Zio XT is only appropriate for less serious arrhythmias. In 2019, iRhythm launched the Zio AT, which added a wearable cellular gateway to transmit patient data to iRhythm’s ZEUS System. Marketed by iRhythm as a mobile cardiac telemetry (MCT) device, this transmission capability is meant to enable real-time surveillance and notification to doctors of cardiac events for more acute patients.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c89e7439-2295-4b7a-afe3-48a80f5b8d1a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.65, "x": 0.31, "y": 0.03 }, "kind": "title", "text": "Spruce Point Issues \"Strong Sell\" Opinion On iRhythm Technologies, Inc. (Nasdaq: IRTC)", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "06926038-0d03-476b-8efb-4425a2021b53", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.02, "y": 0.64 }, "kind": "title", "text": "A Single Product, Single Market, Single Application Company", "attrs": null, "subkind": "subtitle", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "59e1f71d-9b8c-492d-9054-45456ff51020", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "AIDA Model", "slug": "aida-model", "agent": "Storyteller", "layer": "slide", "matchId": "16f23c34-9a91-4482-9830-eabb64c25d79", "evidence": "The slide attempts to grab attention with a strong statement ('We disagree and see 40% to 70% downside risk') and provides some information to support the claim.", "confidence": 0.5 }, { "name": "Thesis archetype", "slug": "thesis-archetype", "agent": null, "layer": "slide", "matchId": "b25daa55-22b3-4c5f-b015-b075b3e021b8", "evidence": "The slide presents a clear opinion on iRhythm Technologies, Inc. with a specific call to action ('Strong Sell'), which is a common archetype for a thesis.", "confidence": 0.7 } ], "frameworks": [], "arcBeats": [ { "to": 7, "from": 1, "beatId": "c8c74bb9-8293-469b-982a-c8048c9a2668", "arcName": "Overcoming the Monster", "arcSlug": "overcoming-monster", "beatName": "Villain Critique", "beatSlug": null, "evidence": "The initial pages set the tone for criticizing iRhythm and its management.", "position": 0, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }